18 and older, female only, with Contraception. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Proportion of Participants With an IUD Expulsion (Complete) at 6 MonthsPrimary· 6 months postpartum
Complete IUD expulsion will be defined as an IUD which no longer in the uterus on speculum exam and transvaginal ultrasound will be performed on all patients at 6 months postpartum to confirm IUD use
Group
Value
95% CI
Interval Postpartum IUD Placement
0
Early Postpartum IUD Placement
3
Proportion of Participants Using an IUD at 6 MonthsSecondary· 6 months postpartum
IUD utilization will be defined as intrauterine use of an IUD at 6 months postpartum. A speculum exam and transvaginal ultrasound will be performed on all patients at 6 months postpartum to confirm IUD use
Group
Value
95% CI
Interval Postpartum IUD Placement
139
Early Postpartum IUD Placement
141
Proportion of Participants With an IUD Expulsion (Partial) at 6 MonthsSecondary· 6 months
Partial IUD expulsions will be diagnosed in any participant found to have an IUD in which part of the body of the IUD is noted to be coming through the external cervical os on speculum exam.
Group
Value
95% CI
Interval Postpartum IUD Placement
11
Early Postpartum IUD Placement
14
Proportion of Participants With a Pelvic Infection Within 6 MonthsSecondary· 6 months
Pelvic infection requiring antibiotics will be ascertained by patient report and/or medical record review.
Group
Value
95% CI
Interval Postpartum IUD Placement
0
Early Postpartum IUD Placement
3
Patient Satisfaction With IUD Assessed on a Five-point "Likert" Scale for Satisfaction, an Ordinal Scale That Measure Levels of Agreement/DisagreementSecondary· 6 months
Participants are asked how much they agree with the statement "I am satisfied with using this IUD." Answers are valued 1-5, with 1 Strongly Agree, 2 Agree, 3 Neutral, 4 Disagree, and 5 Strongly Disagree. 1=Strongly Agree is considered the best outcome, 5=Strongly disagree is considered the worst outcome. Outcome reported is those who were very satisfied or satisfied.
Group
Value
95% CI
Interval Postpartum IUD Placement
116
Early Postpartum IUD Placement
129
Proportion of Participants With an IUD Perforation at 6 MonthsSecondary· 6 months
IUD perforations through the uterus will be diagnosed when an IUD visible is not visible on transvaginal ultrasound of the uterus but is visible on x-ray of the abdomen or pelvis.
Group
Value
95% CI
Interval Postpartum IUD Placement
0
Early Postpartum IUD Placement
0
Sponsor's own description
Intrauterine devices (IUDs) are historically placed at a six-week postpartum visit for women who desire intrauterine contraception after delivery. A two-week postpartum visit could be a convenient time for women to receive contraception, including IUDs. Offering women IUDs at two-weeks postpartum may decrease the risk of undesired pregnancy and rapid repeat pregnancy. This study will compare IUD insertion at two different times after delivery: two-weeks and six-weeks postpartum. This will allow researchers to assess whether the timing of IUD placement affects whether an IUD is expelled, or pushed out of it's ideal location.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT04932382 — Misoprostol Prior to Intrauterine Device Insertion
· NA
· completed
NCT02827487 — Tramadol Versus Celecoxib in Reducing Pain Associated With IUD Insertion
· Phase 4
· unknown
NCT02595125 — Study Assessing the Reduction of Pain Felt During Installation Intra- Uterine Device by Direct Technique
· NA
· completed
Other recruiting trials for Contraception
Currently open trials in the same condition.
NCT07365904 — Investigating Ovulation Inhibition for Use as a Contraceptive
· Phase 2
· recruiting
NCT07437495 — Women's Knowledge of Contraception During the Postpartum Period
· active not recruiting
NCT06823037 — Hormonal Contraception Access Through Pharmacist Prescribing Implementation
· NA
· recruiting
NCT07326007 — Verbal Analgesia Versus Standard Technique for Pain Control During Copper T380A Intrauterine Device Insertion in Women W
· NA
· recruiting
NCT05910580 — Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years
· NA
· recruiting
Other University of California, San Diego trials
Trials by the same sponsor.
NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care
· NA
· not yet recruiting
NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease
· NA
· not yet recruiting
NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes
· Phase 3
· not yet recruiting
NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples
· NA
· not yet recruiting
NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2)
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
Last refreshed: 13 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03462758.